Skip to content
Nonprofiteer
← OVARIAN CANCER RESEARCH FUND INC

Form 990 for tax year 2023

Filed by OVARIAN CANCER RESEARCH FUND INC.

This return was superseded by a later amendment. matched by us It is kept because history is preserved rather than replaced.

What the amendment changed

Compared with the latest return for 2023 , filed 13 November 2025. matched by us Only the return's totals, a 990-PF's accounting method and the names listed in Part VII (Part VIII on a 990-PF) are compared. We relate returns by organization, tax year and form, and order them by each return's own timestamp; the filer's own "amended return" checkbox is a separate fact.

Those are the same on the two returns, so the amendment changed something else.

Totals

Total revenue
$13,442,515
Total expenses
$13,752,760
Contributions and grants received
$11,556,311
Grants paid
$8,117,910
Program service revenue
$438,937
Investment income
$1,447,267
Other revenue
$0
Total assets, end of year
$39,203,357
Total liabilities, end of year
$14,720,293
Net assets or fund balances, end of year
$24,483,064
Program services expenses (Part IX)
$11,116,441
Management and general expenses
$1,220,617
Fundraising expenses
$1,415,702
Program service expenses (Part III)
$11,116,441

Program services were 80.8% of total expenses calculated — Part IX's program-services column over total expenses, both as filed.

Line items

Every line the filer filed in Parts VIII, IX and X, as filed and in filed order. Blank columns are left out, and the lines are not forced to add up to the totals above.

Revenue

Part VIII, the statement of revenue.

  • 1c · Fundraising events

    $1,160,499

  • 1f · All other contributions, gifts and grants

    $10,395,812

  • 1g · Noncash contributions included above

    $2,797,584

  • 2a · Program service revenue: CONFERENCE

    total $438,937 · related or exempt $438,937

  • 3 · Investment income

    total $1,095,100 · excluded $1,095,100

  • 7a · Gross sales of assets other than inventory

    securities $24,562,455

  • 7b · Less cost or other basis and sales expenses

    securities $24,210,288

  • 7c · Gain or loss

    securities $352,167

  • 7d · Net gain or loss

    total $352,167 · excluded $352,167

  • 8a · Fundraising events: gross income

    $145,898

  • 8a · Fundraising events: contributions included on line 1c

    $1,160,499

  • 8b · Fundraising events: direct expenses

    $145,898

  • 8c · Net income from fundraising events

    total $0

Functional expenses

Part IX, the statement of functional expenses.

  • 1 · Grants to domestic organizations and governments

    total $7,397,910 · program services $7,397,910

  • 3 · Grants to foreign organizations and individuals

    total $720,000 · program services $720,000

  • 5 · Compensation of officers, directors and key employees

    total $576,063 · program services $247,748 · management and general $241,887 · fundraising $86,428

  • 7 · Other salaries and wages

    total $1,887,757 · program services $983,575 · management and general $246,307 · fundraising $657,875

  • 8 · Pension plan contributions

    total $57,486 · program services $30,017 · management and general $6,823 · fundraising $20,646

  • 9 · Other employee benefits

    total $358,801 · program services $185,282 · management and general $56,396 · fundraising $117,123

  • 10 · Payroll taxes

    total $184,609 · program services $92,726 · management and general $35,344 · fundraising $56,539

  • 11b · Fees: legal

    total $40,512 · management and general $40,512

  • 11c · Fees: accounting

    total $83,213 · management and general $83,213

  • 11f · Fees: investment management

    total $78,481 · management and general $78,481

  • 11g · Fees: other

    total $637,844 · program services $423,783 · management and general $214,061

  • 12 · Advertising and promotion

    total $103,007 · program services $51,503 · management and general $19,572 · fundraising $31,932

  • 13 · Office expenses

    total $303,836 · program services $79,546 · management and general $41,034 · fundraising $183,256

  • 14 · Information technology

    total $277,972 · program services $139,621 · management and general $53,218 · fundraising $85,133

  • 16 · Occupancy

    total $156,400 · program services $78,558 · management and general $29,942 · fundraising $47,900

  • 17 · Travel

    total $56,824 · program services $46,336 · management and general $10,488

  • 19 · Conferences, conventions and meetings

    total $287,193 · program services $287,193

  • 23 · Insurance

    total $18,366 · program services $9,225 · management and general $3,516 · fundraising $5,625

  • 24a · Other expenses: GENETIC TESTING

    total $285,602 · program services $285,602

  • 24b · Other expenses: MISCELLANEOUS

    total $103,750 · program services $52,112 · management and general $19,863 · fundraising $31,775

  • 24c · Other expenses: CREDIT CARD CHARGES

    total $87,992 · fundraising $87,992

  • 24d · Other expenses: BANK FEES

    total $19,480 · management and general $19,480

  • 24e · All other expenses

    total $29,662 · program services $5,704 · management and general $20,480 · fundraising $3,478

Balance sheet

Part X, book values.

  • 2 · Savings and temporary cash investments

    beginning of year $7,221,319 · end of year $3,782,283

  • 4 · Accounts receivable

    beginning of year $6,857,210 · end of year $669,631

  • 9 · Prepaid expenses and deferred charges

    beginning of year $72,866 · end of year $112,347

  • 10a · Land, buildings and equipment: cost or other basis

    $223,290

  • 10b · Land, buildings and equipment: accumulated depreciation

    $220,915

  • 10c · Land, buildings and equipment, net

    beginning of year $14,449 · end of year $2,375

  • 11 · Investments: publicly traded securities

    beginning of year $22,022,779 · end of year $34,459,485

  • 15 · Other assets

    beginning of year $1,470,465 · end of year $177,236

  • 17 · Accounts payable and accrued expenses

    beginning of year $196,109 · end of year $247,245

  • 18 · Grants payable

    beginning of year $13,020,131 · end of year $14,388,180

  • 25 · Other liabilities

    beginning of year $1,612,582 · end of year $84,868

  • 27 · Net assets without donor restrictions

    beginning of year $20,616,851 · end of year $13,689,736

  • 28 · Net assets with donor restrictions

    beginning of year $2,213,415 · end of year $10,793,328

Mission and programs · 2023

Mission

OVARIAN CANCER RESEARCH ALLIANCE (OCRA) IS COMMITTED TO PREVENTING, DEVELOPING BETTER TREATMENTS FOR AND ULTIMATELY CURING OVARIAN AND RELATED GYNECOLOGIC CANCERS THROUGH INNOVATIVE RESEARCH, RAISING AWARENESS AND ENSURING THE BEST CARE POSSIBLE THROUGH ADVOCACY AND SUPPORT FOR PATIENTS AND FAMILIES.

Activities or mission (Part I)

SEE SCHEDULE O FOR ORGANIZATION MISSION STATEMENT

  • OVARIAN CANCER RESEARCH ALLIANCE WAS FOUNDED IN 1994 (AS THE OVARIAN CANCER RESEARCH FUND, INC.) AND IS A FULL-SPECTRUM ORGANIZATION FUNDING MEDICAL RESEARCH, ADVOCATING ON BEHALF OF PATIENTS AND PROVIDING SUPPORT AND RESOURCES TO PATIENTS AND THEIR FAMILIES. OVARIAN CANCER IS THE DEADLIEST OF ALL GYNECOLOGIC CANCERS AND RANKS FIFTH AS THE CAUSE OF CANCER DEATH IN WOMEN. EACH YEAR THERE WILL BE OVER 19,000 NEW CASES OF OVARIAN CANCER IN THE UNITED STATES, AND APPROXIMATELY 14,000 WOMEN WILL DIE OF THE DISEASE. THE ACCOMPLISHMENTS OF OCRA'S PROGRAMS REFLECT OUR COMMITMENT TO THE OVARIAN AND GYNECOLOGIC CANCER COMMUNITIES. SINCE 1998, OCRA HAS AWARDED 418 GRANTS FOR OVARIAN AND RELATED CANCER RESEARCH TO PHYSICIANS AND SCIENTISTS AT 98 LEADING MEDICAL CENTERS, WHICH IS AN INVESTMENT TOTALING OVER $122 MILLION. THANKS TO THE GENEROSITY OF OUR DONORS, OUR INVESTIGATORS ARE WORKING ON MANY FRONTS TO DEFEAT OVARIAN CANCER. BY DEVELOPING INNOVATIVE STRATEGIES FOR EARLY DETECTION AND EXPLORING THE GENETICS THAT INCREASE RISK FOR OVARIAN CANCER, WE HOPE TO SAVE WOMEN'S LIVES BY FINDING THE CANCER EARLY OR STOPPING IT BEFORE IT EVEN STARTS. RESEARCHERS ARE GAINING INSIGHTS INTO THE MANY TYPES OF OVARIAN AND RELATED CANCERS TO DETERMINE THE ORIGINS, WHICH MAY LEAD TO MORE EFFECTIVE TESTING AND EFFECTIVE IMMUNOTHERAPY TREATMENT OPTIONS. FURTHERMORE, THEY ARE IDENTIFYING NEW AND BETTER TREATMENTS TO IMPROVE OVERALL SURVIVAL, PREVENT DRUG RESISTANCE, MINIMIZE SIDE EFFECTS, PREVENTING RECURRENCE AND METASTASIS, AND ENHANCE PATIENTS' QUALITY OF LIFE. FINALLY,OCRA LAUNCHED A NEW GRANT - HEALTH EQUITY RESEARCH GRANT AND AWARDED 3 IN ITS FIRST YEAR. THESE GRANTS WILL FOCUS ON IMPROVING HEALTH EQUITY IN THE GYNECOLOGIC CANCER SPACE.ACCOMPLISHMENTS ACHIEVED AS A RESULT OF OCRA GRANTS INCLUDE: SHOWN THAT RUCAPARIB EXTENDS PROGRESSION FREE SURVIVAL IN OVARIAN CANCER; HELPED EXPLAIN RESISTANCE TO CHEMOTHERAPY; DISCOVERED THAT 18% OF OVARIAN CANCER CASES INVOLVE INHERITED MUTATIONS; EXPLORED THE ROLE OF ESTROGEN IN ANTI-TUMOR IMMUNITY; PINPOINTED TWO GENES THAT TRIGGER OVARIAN CANCER; IDENTIFIED A NEW THERAPEUTIC STRATEGY FOR CLEAR CELL OVARIAN CANCER; SHOWN HOW A PARP/IMMUNE THERAPY COMBO SHOWS PROMISE; DEMONSTRATED HOW GENE THERAPY MAY HELP PATIENTS WITH RECURRENT DISEASE; CONFIRMED GENERIC HEART MEDICATION CAN PROLONG SURVIVAL IN OVARIAN CANCER PATIENTS; SHED LIGHT ON HOW OVARIAN CANCER GROWS; DISCOVERED THAT ANALYZING DATA FROM PAP SMEARS COULD HELP DETECT ENDOMETRIAL AND OVARIAN CANCER; ESTABLISHED THERE IS NO LINK BETWEEN OBESITY AND RISK FOR THE MOST COMMON TYPE OF OVARIAN CANCER; SHOWN THAT FGFR4 IS A PROGNOSTIC MARKER AND THERAPEUTIC TARGET FOR OVARIAN CANCER; FOUND THAT A SUBSET OF IMMUNE CELLS PROMOTE TUMOR GROWTH; CLARIFIED WHICH CELL LINES ARE THE BEST FIT FOR USE IN OVARIAN CANCER RESEARCH; DEFINED SIMILARITIES BETWEEN SOME ENDOMETRIAL, BREAST AND OVARIAN CANCERS; EXPLAINED HOW AN EXPERIMENTAL DRUG MAY BE HELPFUL IN FIGHTING PLATINUM-RESISTANT OVARIAN CANCER; IDENTIFIED AREAS OF THE HUMAN GENOME THAT ARE LINKED TO INCREASED RISK FOR OVARIAN CANCER; EVALUATED NEW EXPERIMENTAL MODELS TO ADVANCE OVARIAN CANCER RESEARCH; REVEALED HOW COMBINING TARGETED AGENTS IS EFFECTIVE; IDENTIFIED BIOMARKERS THAT CAN BE USED TO MONITOR THE DEVELOPMENT OF PLATINUM RESISTANCE THERAPIES; STUDIED MACROPHAGES TO IMPROVE TREATMENT; IDENTIFIED NOVEL BIOMARKERS OF HGSOC AND SPECIFIC DRUG TARGETS; TARGETED MDM2 DEGRADATION AS A NOVEL TREATMENT FOR OVARIAN CANCER; USED MACHINE LEARNING TO BRIDGE THE GAP BETWEEN DISPARATE DATA SETS SPECIFICALLY IN PATIENTS WITH HGSOC; DOSED THE FIRST PATIENTS IN THE CLINICAL TRIAL "IMMUNOTHERAPY PLATFORM STUDY IN PLATINUM RESISTANT HIGH GRADE SEROUS OVARIAN CANCER (IPROC)" (NCT04918186); FOUND KEY PROTEINS IN HGSOC CANCER CELLS WHICH RESULTED IN COMBINED TREATMENT OPTIONS WHICH RESULTED IN SMALLER TUMORS AND LONGER SURVIVAL; AND SHOWED HOW SURGICAL REMOVAL OF FALLOPIAN TUBES MAY REDUCE OVARIAN CANCER RISK.IN 2023 ALONE, OCRA RESEARCHERS: IDENTIFIED A MOLECULE THAT COULD BE A KEY TO IMPROVING IMMUNE RESPONSE AGAINST OVARIAN CANCER; IDENTIFIED RNA-BINDING PROTEIN GENES AS ANOTHER POTENTIAL SOURCE OF HEREDITARY CANCERS, IN ADDITION TO MORE WELL-KNOWN GENES LIKE BRCA 1/2; SET OUT TO UNDERSTAND HOW CANCER SPREADS AND HOW CANCER CELLS RELY ON/DEPLOY ENERGY SOURCES LIKE SUGAR AND FAT TO SURVIVE TO FIND BETTER TREATMENTS; HIGHLIGHTED THE NEED FOR INDIVIDUAL ASSESSMENT OF COMPLEX VARIANTS TO CORRECTLY IDENTIFY INDIVIDUALS AT RISK; SOUGHT TO UNDERSTAND WHY CERTAIN OVARIAN CANCER CELLS RESIST OLAPARIB TREATMENT, AND DISCOVERED THAT INTRODUCING A SECOND DRUG (MIFEPRISTONE) WHILE TARGETING CERTAIN CELLS (POLYPLOID GIANT CANCER CELLS) MAY OFFER A SOLUTION; DISCOVERED A NEW APPROACH TO IMMUNOTHERAPY THAT OVERCOMES SOME OF THE CHALLENGES OF TREATING OVARIAN CANCER; IDENTIFIED A PREVIOUSLY UNKNOWN CHEMORESISTANT PATHWAY IN HGSC WHICH LED TO WORKING ON A NEW THERAPY TO OVERCOME THIS; PROVIDED AN OVERVIEW OF POTENTIAL THERAPEUTIC STRATEGIES THAT OBSTRUCT PLATELETS' PROTUMOR EFFECTS BY REPROGRAMMING THE TUMOR MICROENVIRONMENT; FOUND THAT MESOTHELIAL CELLS ARE IMPORTANT TO THE INITIAL STAGES OF OVARIAN CANCER GROWTH IN THE ABDOMINAL CAVITY; PROVIDED A NEW THERAPEUTIC STRATEGY TO OVERCOME TME-MEDIATED RESISTANCE TO PARPI ; SHED NEW LIGHT ON HOW THE MOST COMMON SUBTYPE OF OVARIAN CANCER DEVELOPS AND METASTASIZES, BY IDENTIFYING A KEY MOLECULE THAT ALLOWS MALIGNANCIES IN THE FALLOPIAN TUBE TO MIGRATE TO THE OVARIES AND CONTINUE TO GROW; AND UNCOVERED SEVERAL MECHANISMS OF IMMUNE ESCAPE THAT CAN HELP EXPLAIN WHY OVARIAN CANCERS HAVE BEEN RESISTANT TO IMMUNOTHERAPY TO DATE. EVERY DOLLAR DONATED BRINGS US CLOSER TO A CURE FOR THIS DEVASTATING DISEASE. FOR MORE INFORMATION OR TO JOIN US IN OUR FIGHT, PLEASE VISIT OCRA'S WEBSITE AT WWW.OCRAHOPE.ORG.

    Expenses $8,675,579 · Grants $8,117,910

  • EACH YEAR, OCRA BRINGS TOGETHER OVARIAN CANCER PATIENTS, SURVIVORS AND CAREGIVERS AT THE OVARIAN CANCER NATIONAL CONFERENCE, A THREE DAY-LONG EVENT FILLED WITH INFORMATIONAL SESSIONS FEATURING EXPERT SPEAKERS, FUN AND COMMUNITY. MORE THAN 605 PEOPLE FROM ALL AROUND THE WORLD COME TOGETHER VIRTUALLY FOR THIS EVENT. THE SPIRIT OF UNITY AND HOPE IS ALWAYS STRONG AND ATTENDEES CAN LEARN MORE ABOUT THEIR DIAGNOSIS, TREATMENT, AND SURVIVORSHIP. SESSIONS FEATURE TOP OVARIAN CANCER EXPERTS WHO GENEROUSLY GIVE OF THEIR TIME, PRESENTING THE LATEST IN TREATMENTS, RESEARCH, MANAGING RECURRENCE, GENETICS, NUTRITION, CARETAKER AND SUPPORTER CARE, SUPPORT FOR YOUNG WOMEN, ADVOCACY, AND SO MUCH MORE.

    Expenses $586,412 · Revenue $438,937

  • BEYOND OUR CONFERENCE, OCRA HAS ADDITIONAL PATIENT EDUCATION AND SUPPORT PROGRAMS AND ENGAGES IN ADVOCACY ON BEHALF OF WOMEN WITH GYNECOLOGIC CANCERS. OUR WEBSITE IS A COMPREHENSIVE SOURCE OF EDUCATIONAL INFORMATION, AND THROUGHOUT THE COURSE OF THE YEAR WE HOLD A SERIES OF FREE, EDUCATIONAL WEBINARS ON A RANGE OF TOPICS RELATED TO THE LATEST RESEARCH, TREATMENT, AND SURVIVORSHIP. OCRA'S PATIENT-SUPPORT LINE IS STAFFED BY OUR SOCIAL WORK TEAM DURING BUSINESS HOURS MONDAY THROUGH FRIDAY AND IS AVAILABLE TO ANYONE SEEKING INFORMATION, SUPPORT, PATIENT NAVIGATION, OR RESOURCE REFERRALS (MEDICAL ADVICE IS NOT PROVIDED). OUR WOMAN TO WOMAN PROGRAM IS A PEER-TO-PEER SUPPORT PROGRAM FOR WOMEN WITH GYNECOLOGIC CANCER. OCRA OFFERS BOTH A NATIONAL WOMAN TO WOMAN PROGRAM AND PROVIDES FINANCIAL SUPPORT TO HELP HOSPITALS AND OTHER ORGANIZATIONS START LOCAL WOMAN TO WOMAN PROGRAMS, WHICH ARE NOW AT MORE THAN 24 SITES ACROSS THE COUNTRY. OUR STAYING CONNECTED SUPPORT SERIES, WHICH LAUNCHED IN 2020, NOW OFFERS FOUR WEEKLY WORKSHOPS AND THREE MONTHLY WORKSHOPS WHICH ENABLES ALL IMPACTED BY OVARIAN OR RELATED GYNECOLOGIC CANCERS A WAY TO LEARN, SHARE, AND CONNECT. OUR ARTS PROGRAM, EXPRESS YOURSELF, OFFERS A COMBINATION OF THERAPEUTIC ARTS, POETRY, AND COMMUNITY BUILDING ACTIVITIES. OCRA PARTNERS WITH INSPIRE.COM TO OFFER AN ONLINE SUPPORT COMMUNITY THAT HAS OVER 80,000 MEMBERS WORLD-WIDE. OCRA IS COMMITTED TO ENCOURAGING THE NEXT GENERATION OF HEALTHCARE PROFESSIONALS TO FOCUS ON THE CRITICAL NEEDS OF THOSE DIAGNOSED WITH GYNECOLOGIC CANCER, WHETHER AT BENCH OR BEDSIDE. THROUGH OCRA'S ONCOLOGY SOCIAL WORK FIELD PLACEMENT, WE ACCEPT TOP MASTER OF SOCIAL WORK CANDIDATES TO TRAIN WITH OUR LICENSED CLINICAL SOCIAL WORKERS TO ADDRESS THE SPECIFIC NEEDS OF OUR COMMUNITY. OCRA'S SURVIVORS TEACHING STUDENTS (STS) PROGRAM TRAINS OVARIAN CANCER SURVIVORS AND CAREGIVERS TO CONDUCT PRESENTATIONS IN MEDICAL EDUCATION PROGRAMS TO EDUCATE FUTURE HEALTHCARE PROVIDERS ABOUT OVARIAN CANCER. SURVIVORS SHARE THEIR STORIES OF DIAGNOSIS, TREATMENT AND BEYOND, ALONG WITH FACTS ABOUT THE DISEASE. EACH YEAR, MORE THAN 1,000 SURVIVOR VOLUNTEERS DELIVERED PRESENTATIONS AT 405+ SCHOOLS IN 41 STATES (AS WELL AS UK, CANADA AND AUSTRALIA), AND REACH OVER 10,000 MEDICAL, NURSING, AND PHYSICIAN'S ASSISTANT STUDENTS. THESE PRESENTATIONS ENSURE THE NEXT GENERATION OF HEALTH CARE PROVIDERS UNDERSTAND BASIC FACTS ABOUT THE DISEASE, ARE AWARE OF RISK FACTORS, AND CAN IDENTIFY THE SIGNS AND SYMPTOMS OF OVARIAN CANCER, HELPING ENSURE A TIMELY DIAGNOSIS. OVARIAN CANCER RESEARCH ALLIANCE IS A POWERFUL VOICE ON CAPITOL HILL, IN STATEHOUSES AROUND THE COUNTRY AND WITH FEDERAL AGENCIES FOR EVERYONE TOUCHED BY GYNECOLOGIC CANCER . EACH YEAR OCRA PLAYS A CRITICAL ROLE IN HELPING TO SECURE MORE THAN $200 MILLION IN FEDERAL FUNDING FOR OVARIAN CANCER RESEARCH AND EDUCATION. IN ADDITION, OUR GROWING ADVOCATE LEADER PROGRAM TRAINS MEMBERS OF THE GYNECOLOGIC CANCER COMMUNITY TO RAISE AWARENESS THROUGH NEWS ARTICLES AND OUTREACH, DEVELOP RELATIONSHIPS WITH THEIR ELECTED OFFICIALS, AND FIGHT FOR INCREASED FUNDING FOR GYNECOLOGIC CANCER RESEARCH THROUGHOUT THE COUNTRY.

    Expenses $1,854,450

As filed on the 2023 return. The filer continues this part on Schedule O, which is not shown here.

Listed in Part VII

  • John Orrico

    CHAIR

    Total calculated
    $0
    Hours/week
    3
  • Matthew Neal Miller

    VICE PRESIDENT

    Total calculated
    $0
    Hours/week
    2
  • Mark Tessar

    TREASURER

    Total calculated
    $0
    Hours/week
    2
  • Robin S Cohen

    SECRETARY

    Total calculated
    $0
    Hours/week
    2
  • Jeannette Chang

    DIRECTOR

    Total calculated
    $0
    Hours/week
    1
  • Dr Carmel J Cohen

    DIRECTOR

    Total calculated
    $0
    Hours/week
    1
  • Mei-Li Da Silva Vint Esq

    DIRECTOR

    Total calculated
    $0
    Hours/week
    1
  • Andrew Feuerstein

    DIRECTOR

    Total calculated
    $0
    Hours/week
    1
  • Carol J Hamilton

    DIRECTOR

    Total calculated
    $0
    Hours/week
    1
  • John W Hansbury Esq

    DIRECTOR

    Total calculated
    $0
    Hours/week
    1
  • Caroline Hirsch

    DIRECTOR

    Total calculated
    $0
    Hours/week
    1
  • Veronica Jordan

    DIRECTOR

    Total calculated
    $0
    Hours/week
    1
  • Thomas C Liebman

    DIRECTOR

    Total calculated
    $0
    Hours/week
    1
  • Dana L Mark Esq

    DIRECTOR

    Total calculated
    $0
    Hours/week
    1
  • Ylain G Mayer

    DIRECTOR

    Total calculated
    $0
    Hours/week
    1
  • Chris Newcomb

    DIRECTOR

    Total calculated
    $0
    Hours/week
    1
  • Lisa Schreiber

    DIRECTOR

    Total calculated
    $0
    Hours/week
    1
  • Elle Simone Scott

    DIRECTOR

    Total calculated
    $0
    Hours/week
    1
  • Christopher Tilberis

    DIRECTOR

    Total calculated
    $0
    Hours/week
    1
  • Audra L Moran

    PRESIDENT & CEO

    Total calculated
    $345,710
    From this org
    $312,816
    From related orgs
    $0
    Other
    $32,894
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $312,816
    Bonus
    $0
    Other
    $0
    Deferred
    $12,862
    Nontaxable benefits
    $20,032
    Filer's total
    $345,710
  • Bibi Ali

    CHIEF FINANCIAL OFFICER

    Total calculated
    $230,353
    From this org
    $202,842
    From related orgs
    $0
    Other
    $27,511
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $202,842
    Bonus
    $0
    Other
    $0
    Deferred
    $7,566
    Nontaxable benefits
    $19,945
    Filer's total
    $230,353
  • Jonathan Zeidman

    CHIEF DEVELOPMENT OFFICER

    Total calculated
    $233,344
    From this org
    $204,750
    From related orgs
    $0
    Other
    $28,594
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $204,750
    Bonus
    $0
    Other
    $0
    Deferred
    $0
    Nontaxable benefits
    $28,594
    Filer's total
    $233,344
  • Sarah Defeo

    CHIEF PROGRAM OFFICER

    Total calculated
    $220,226
    From this org
    $183,750
    From related orgs
    $0
    Other
    $36,476
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $183,750
    Bonus
    $0
    Other
    $0
    Deferred
    $7,350
    Nontaxable benefits
    $29,126
    Filer's total
    $220,226
  • Tracy Moore

    VP - SUPPORT & EDUCATION

    Total calculated
    $178,479
    From this org
    $152,500
    From related orgs
    $0
    Other
    $25,979
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $152,500
    Bonus
    $0
    Other
    $0
    Deferred
    $6,100
    Nontaxable benefits
    $19,879
    Filer's total
    $178,479
  • Nicole Wargo

    VP - PHILANTHROPIC PARTNER

    Total calculated
    $154,139
    From this org
    $128,823
    From related orgs
    $0
    Other
    $25,316
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $128,823
    Bonus
    $0
    Other
    $0
    Deferred
    $5,153
    Nontaxable benefits
    $20,163
    Filer's total
    $154,139
  • Chad Ramsey

    VP - POLICY

    Total calculated
    $143,642
    From this org
    $119,107
    From related orgs
    $0
    Other
    $24,535
    Hours/week
    40

Compensation is as filed in Part VII: reportable pay from this organization and from related organizations, other compensation, and hours per week. The total, marked calculated, is our sum of the three dollar columns, with a blank column counted as $0; the form itself has no total. On a Form 990-EZ the columns are Part IV's instead, and on a Form 990-PF Part VIII's — compensation, contributions to benefit plans, and expense account — and the total sums those. A Schedule J breakdown is as filed: base pay, bonus, other, deferred compensation and nontaxable benefits from this organization, with any from related organizations beside each, and the filer's own total. It is shown with the Part VII listing of the same name on the same return. The form gives no key between the two, so that pairing is ours, and is marked matched by us.

Schedule J

Answered yes

  • 3 · Compensation committee
  • 3 · Form 990 of other organizations
  • 3 · Approval by the board or compensation committee

Answered no

  • 4a · Severance or change-of-control payment
  • 4b · Supplemental nonqualified retirement plan
  • 4c · Equity-based compensation arrangement
  • 5a · Pay contingent on this organization's revenues
  • 5b · Pay contingent on a related organization's revenues
  • 6a · Pay contingent on this organization's net earnings
  • 6b · Pay contingent on a related organization's net earnings
  • 7 · Other non-fixed payments
  • 8 · Paid under the initial-contract exception

Part I's answers as filed. A line not listed was left unanswered; on lines 1a and 3 that means the box was not checked.

Grants on this return

The 10 largest by cash amount. The API serves every itemized grant.

Fundraising and gaming

From Schedule G of this return, as filed.

Had an agreement with a professional fundraiser (line 2a)
Not answered

Fundraising events (Part II)

Part II has at most four columns: the two largest events, the rest together, and the total.

Line Event 1 OVARIAN CYCLE Other events 2 events Total
Gross receipts (line 1) $178,798 $1,127,599 $1,306,397
Less contributions (line 2) $159,380 $1,001,119 $1,160,499
Gross income (line 3) $19,418 $126,480 $145,898
Cash prizes (line 4) — — —
Noncash prizes (line 5) — — —
Rent and facility costs (line 6) — — —
Food and beverages (line 7) — — —
Entertainment (line 8) — — —
Other direct expenses (line 9) — — —
Direct expenses (line 10)
—
Net income (line 11)
$145,898

Activities outside the United States

From Schedule F of this return, as filed.

Offices (line 3c)
0
Employees, agents and contractors (line 3c)
0
Expenditures and investments (line 3c)
$720,000

At most 25 lines of each part are listed here. Schedule F names no grantee, so each line is a region and its money.

Activities by region (Part I)

Region Offices Employees Activity Specific services Expenditures
NORTH AMERICA 0 0 AWARDING OF GRANTS AWARDING OF RESEARCH GRANTS $720,000

Grants to organizations, by region (Part II)

The purpose of each grant is not shown.

Region Cash grants Manner of disbursement Noncash assistance Noncash description Valuation
NORTH AMERICA $450,000 — $0 — —
NORTH AMERICA $270,000 — $0 — —
Grantees recognized as charities or with a 501(c)(3) equivalency letter (Part II line 2)
—
Other grantees (Part II line 3)
2
Transferred property to a foreign corporation during the year (line 1)
No
Had an interest in a foreign trust (line 2)
No
Owned an interest in a foreign corporation (line 3)
No
Was a shareholder of a passive foreign investment company or qualified electing fund (line 4)
No
Owned an interest in a foreign partnership (line 5)
No
Had operations in or related to a boycotting country (line 6)
No

Related organizations on this return

Schedule R Part II: tax-exempt organizations related to the filer by control. It does not record shared board members or money.

Provenance

Return type
form_990
Tax year
2023
Filed
14 November 2024
IRS schema version
2023v5.1
Source object
202423199349310332

Check it against the return as filed: the GivingTuesday Data Lake hosts a public copy of the original XML.

The source document this was parsed from is served over the API, which is where bulk and document access live.